Oncology. Multiple indications. One bold move changed the pricing playbook. Watch how Roche did it.

Physician buy-in can make or break an innovative contract. In this episode, we explore real-world strategies to engage prescribers, overcome resistance, and drive adoption.

A bold performance-based contract looked like a win—until a key stakeholder pushed back. In this episode, we explore why stakeholder engagement is critical in Innovative Contracting. in cell and gene therapy.

How are payers responding when costly gene therapies don’t deliver long-term durability? We explore evolving contract models tackling buyer’s remorse in cell and gene therapy.

How a high-cost therapy’s contracts tackled access hurdles across the US, LATAM & Europe—outcome-based models, staged payments & service-linked discounts

In the debut episode of our new short video series: How a bold risk-sharing agreement transformed market access for an oncology treatment—challenging pricing norms and reshaping payer negotiations.